Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Welch

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Frontiers in Oncology|March 30, 2026
Analyzing the effect of neoadjuvant stereotactic ablative body radiotherapy on pancreatic tumor perfusion using computed tomography perfusionJin-Young Bang, Dan Breadner, Timothy Nguyen, et al.
Gynecologic Oncology|September 1, 2014
Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancerDaliah Tsoref, Stephen Welch, Susie Lau, et al.
Breast Cancer Research : BCR|May 4, 2017
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancerStephen K Chia, Susan L Ellard, Mihaela Mates, et al.
Clinical and Translational Science|February 23, 2021
Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse eventsTheodore J Wigle, Brandi L Povitz, Samantha Medwid, et al.
Current Oncology (Toronto, Ont.)|September 27, 2023
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023Essa Al-Mansor, Meghan Mahoney, Maxime Chenard-Poirier, et al.
Breast Cancer Research and Treatment|July 8, 2020
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patientsAdrienne E Borrie, Finnley A Rose, Yun-Hee Choi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 9, 2026
Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysisPauline Corbaux, Benoit You, Iain McNeish, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2023
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysisPauline Corbaux, Benoit You, Rosalind M Glasspool, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 19, 2025
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysisPauline Corbaux, Benoit You, Tatsuo Kagimura, et al.
Nature Communications|March 16, 2023
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinomaAinhoa Madariaga, Swati Garg, Nairi Tchrakian, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Frontiers in Oncology|March 30, 2026
Analyzing the effect of neoadjuvant stereotactic ablative body radiotherapy on pancreatic tumor perfusion using computed tomography perfusionJin-Young Bang, Dan Breadner, Timothy Nguyen, et al.
Gynecologic Oncology|September 1, 2014
Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancerDaliah Tsoref, Stephen Welch, Susie Lau, et al.
Breast Cancer Research : BCR|May 4, 2017
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancerStephen K Chia, Susan L Ellard, Mihaela Mates, et al.
Clinical and Translational Science|February 23, 2021
Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse eventsTheodore J Wigle, Brandi L Povitz, Samantha Medwid, et al.
Current Oncology (Toronto, Ont.)|September 27, 2023
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023Essa Al-Mansor, Meghan Mahoney, Maxime Chenard-Poirier, et al.
Breast Cancer Research and Treatment|July 8, 2020
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patientsAdrienne E Borrie, Finnley A Rose, Yun-Hee Choi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 9, 2026
Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysisPauline Corbaux, Benoit You, Iain McNeish, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2023
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysisPauline Corbaux, Benoit You, Rosalind M Glasspool, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 19, 2025
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysisPauline Corbaux, Benoit You, Tatsuo Kagimura, et al.
Nature Communications|March 16, 2023
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinomaAinhoa Madariaga, Swati Garg, Nairi Tchrakian, et al.
Pageof 8